Tipranavir: all 34 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
• Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive PatientsCompletedNCT00530920Phase 2Results posted
• Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PITerminatedNCT00517192Phase 3Results posted
• Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/RitonavirCompletedNCT00486330Not applicableResults posted
• SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoCTerminatedNCT00440271Phase 3Results posted
• Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected SubjectsCompletedNCT00146328Phase 2/3Results posted
• Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)CompletedNCT00144170Phase 3Results posted
• Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)CompletedNCT00054717Phase 3Results posted
• Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentCompletedNCT02259855Phase 1
• Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male VolunteersCompletedNCT02257021Phase 1
• Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult VolunteersCompletedNCT02253875Phase 1
• Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male VolunteersCompletedNCT02253862Phase 1
• Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of RitonavirCompletedNCT02253836Phase 1
• Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male SubjectsCompletedNCT02253797Phase 1
• Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsCompletedNCT02251795Phase 1
• Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of TipranavirCompletedNCT02251769Phase 1
• Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsCompletedNCT02251158Phase 1
• The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy VolunteersCompletedNCT02251119Phase 1
• Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedNCT02249442Phase 1
• Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without TipranavirCompletedNCT02249130Phase 2
• Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy VolunteersCompletedNCT02245451Phase 1
• Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT02245269Phase 1
• Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy VolunteersCompletedNCT02244190Phase 1
• Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy VolunteersCompletedNCT02243553Phase 1
• Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIVTerminatedNCT02229760Phase 1/2
• Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult VolunteersCompletedNCT02226991Phase 1
• Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy VolunteersCompletedNCT02226978Phase 1
• Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult VolunteersCompletedNCT02195466Phase 1
• Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 HoursCompletedNCT00607958Phase 4
• Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy SubjectsCompletedNCT00344123Phase 1
• Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVCompletedNCT00307502Phase 1
• 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining StudyCompletedNCT00275444Phase 2
• Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment OptionsCompletedNCT00144287Phase 3
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedNCT00056641Phase 2

← Tipranavir overview